Increased Expression of Transforming Growth Factor-β after Cerebral Ischemia in the Baboon: An Endogenous Marker of Neuronal Stress?

Abstract

There has been an increasing interest in recent years in the evaluation of the neuronal and glial responses to ischemic insult. Some cytokines, including transforming growth factor-β (TGF-β), that are overexpressed after experimental stroke in rodents are thought to be implicated in the neuronal processes that lead to necrosis. Thus, such cytokines could predict tissue fate after stroke in humans, although data are currently sparse for gyrencephalic species. The current study addressed the expression pattern of TGF-β1 in a nonhuman primate model of middle cerebral artery occlusion. Focal permanent ischemia was induced for 1 or 7 days in 6 baboons and the following investigations were undertaken: cerebral oxygen metabolism (CMRO₂) positron emission tomography studies, magnetic resonance imaging, postmortem histology, and reverse transcription-polymerase chain reaction. The aim of the current study was to correlate the expression of TGF-β1 to the underlying metabolic and histologic state of the threatened cerebral parenchyma. The authors evidenced increased TGF-β1 mRNA levels (up to 25-fold) in those regions displaying a moderate (20% to 49%) reduction in CMRO₂. The current findings suggest that the greatly enhanced expression of TGF-β1 in the penumbral zones that surround tissue destined to infarction may represent a robust index of potentially salvageable brain. The current investigation, in the nonhuman primate, strengthens the authors' hypothesis, derived from rodent models, that TGF-β1 may be involved in the physiopathology of human stroke.

Keywords

Baboon Focal cerebral ischemia PET Transforming growth factor-β

Hypoxia–ischemia insults to the central nervous system initiate various biologic processes that lead to neuronal and glial death. For therapeutic reasons, increasing interest exists to evaluate and mitigate the suffering of the cerebral parenchyma after an ischemic episode. In the last few years, various cytokines (interleukin-1β, interleukin-6, tumor necrosis factor-α, and transforming growth factor-β), the expression of which is enhanced in the ischemic rodent brain (DeGraba, 1998; Feuerstein et al., 1998), have been suggested to represent potential predictors of neurologic outcome after stroke. Among these cytokines, transforming growth factor-β (TGF-β) has elicited clinical interest, because Krupinski and collaborators (1996) have evidenced an increased immunoreactivity for TGF-β1 in the infarcted and penumbral brain areas of stroke patients.

Transforming growth factor-βs belong to a family of related peptides that play pivotal roles in intercellular communication (Massague, 1990; Bonewald, 1999). Transforming growth factor-β1 is the prototype of three different isoforms in mammalian species (TGF-β1, TGF-β2, and TGF-β3) that share a common set of serine and threonine kinase receptors (TßR-I and TßR-II) to transduce their biologic signal (Massague, 1996; ten Dijke et al., 2000). The cellular responses to these pleiotropic cytokines occur through the ligand-induced heteromeric complex formation of TßR-I and TßR-II as follows: the type II receptor binds TGF-β, then recruits and phosphorylates the type I receptor, allowing the transphosphorylation-mediated activation of this latter. The subsequent activation of the signaling mother against decapentaplegic peptide (Smad) transcription factor cascade thus regulates the transcription of key target genes involved in the control of the cell cycle and extracellular matrix metabolism (Attisano and Wrana, 2000; Massague and Wotton, 2000; Zimmerman and Padgett, 2000).

Transforming growth factor-β has been found to be abundantly expressed in brain biopsies from patients with chronic neurodegenerative or acute neurologic disorders, such as Parkinson's disease, Alzheimer's disease, or stroke (Pratt and McPherson, 1997). Consequently, this growth factor has been characterized as an injury-related peptide. Despite some opposing data, most of the in vitro studies have led to a consensual concept of a neuroprotective activity for TGF-β (Prehn et al., 1993; 1994; Prehn and Miller, 1996; Henrich-Noack et al., 1996), particularly with regard to the excitotoxic necrotic pathway, a major component of ischemic processes (Choi, 1996). In a model of primary murine cortical cultures, the authors have demonstrated previously that TGF-β1 exerts a selective neuroprotective activity against N-methyl-d-aspartate receptor-mediated neuronal death and that this neuroprotective activity is mediated by astrocytes (Buisson et al., 1998; Docagne et al., 1999). As previously reported (Wang et al., 1995; Lehrmann et al., 1998), the authors have found that in the rat brain the transcriptional activity of TGF-β1 is increased after middle cerebral artery occlusion (MCAO) (Ruocco et al., 1999). In the same study, the authors addressed the relevance of this endogenous production of TGF-β in the ischemic brain. The blockade of the biologic activity of TGF-β, induced by the local injection of a soluble TGF-β type II receptor (TGF-β antagonist), markedly exacerbated both excitotoxic and ischemic lesions. Overall, the latter studies suggest that the endogenous synthesis of TGF-β1 may play a key role in the pathophysiology of cerebral ischemia. Accordingly, to further investigate the potential and promising therapeutic interest of the TGF-β pathway, the goal of the current study was to determine the expression pattern of TGF-β1 as a function of the degree of ischemic injury estimated by both anatomo-pathologic and metabolic approaches. The authors thus combined magnetic resonance imagery (MRI), positron emission tomography (PET), histology, and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) to correlate gene expression with metabolic parameters after focal permanent cerebral ischemia in the nonhuman primate (baboon).

The current findings suggest that the expression of TGF-β1 may represent an endogenous adaptive response of the brain, and thus may be a pertinent index of neuronal stress and ischemic damage. Moreover, the current data strengthen, in the nonhuman primate, the hypothesis derived from rodent models that suggests that TGF-β is a promising therapeutic target for the treatment of cerebral ischemia in humans.

MATERIALS AND METHODS

Surgical procedures

Male baboons (Papio anubis, body weight ≈ 15 kg) were housed in individual cages maintained at 24°C with 50% relative humidity on a 12 hours light/12 hours dark cycle and were fed commercial chow supplemented with fresh fruits and water ad libitum. All experiments were performed according to the French national legislation that governs animal experimentation. The research protocols were approved by the Scientific Council of the authors' institution. A team of external veterinary surgeons was responsible for the animals' health and welfare.

As described previously (Young et al., 1996), the baboons were anesthetized, curarized, and ventilated with 67% nitrous oxide in oxygen under etomidate (0.3 mg/kg · h). Permanent MCAO was performed in six baboons. During surgical interventions, anesthesia was supplemented with isoflurane (0.5% to 1.5%). The transorbital approach to the right MCA was used. After enucleation, a small craniectomy was performed using a saline-cooled surgical drill to expose the MCA. The dura mater was opened and the arachnoid was dissected to allow the placement of two microvascular clips—on the proximal part of the main MCA trunk and on the orbitofrontal branch. The only variability encountered in the anatomic presentation lied in the more or less proximal origin of the orbitofrontal artery. This artery was unique in all cases and bifurcated after a short common trunk into two secondary branches—one lateral following the cortical orbital surface of the frontal lobe, and the other medial, recurrent towards the interhemispheric fissure and presumably giving rise to the lenticulostriate perforating arteries.

In all cases, the two aneurysm clips were placed in the following way: one small clip at the origin of the orbital frontal artery, proximal to both the lateral (cortical) and medial branches; a larger clip on the main MCA trunk (M1), just distal to the origin of the orbito-frontal artery and therefore, proximal to the origin of more lateral division branches (temporal and lateral frontal) of the MCA. Warmed saline was used to reduce the possibility of vascular spasm during these procedures.

Reconstruction of the orbit was performed under aseptic conditions and as follows: the craniectomy was covered by an absorbable collagen coated mesh (Vicryl Collagéne; Ethicon, Neuilly, France) and held in place with tissue adhesive (Histoacryl®; B. Braun Melsungen AG, Melsungen, Germany) applied to the sphenoid; the mesh then was covered with cement (GC Fuji I; GC Corporation, Tokyo, Japan). Thereafter, a silicon prosthesis (14 to 16 mm in diameter) was positioned in the orbit, and 1-cm squares of hemostatic collagen compresses (Panegen® Laboratoires Fournier, Dijon, France) were loosely applied around it. A local antibiotic (Rifocine® Merrell Dow, Levallois-Perret, France) then was applied to the orbit and a tarsorrhaphy was performed. These procedures allowed for a complete postoperative recovery in all baboons.

Physiologic (arterial pressure, heart rate, temperature) and biochemical (Paco₂, Pao₂, pH, hematocrit, hemoglobin, arterial glucose levels) parameters were monitored to maintain optimal conditions during and after the occlusion.

Positron emission tomography procedures

Approximately two weeks before the occlusion, a control MRI (T₂) analysis was performed, as described previously (Young et al., 1996). Thereafter, cerebral oxygen metabolism (CMRO₂) was measured during a baseline PET session with a 64-slice Siemens HR⁺ PET Camera (Siemens, Germany); these measurements were further repeated after occlusion (MCAO + 24 hours or MCAO + 7 days). To obtain reproducible head positioning (both inter-and intraanimal) the baboon's head was fixed in a specially designed frame with ear bars being placed in the bony portion of the external auditory canal and checked by a laser beam. Using the ¹⁵O₂ steady-state technique (with measured attenuation correction), parametric imaging of CMRO₂ corrected for blood volume was determined (Frackowiak et al., 1980; Sette et al., 1989).

After 24 hours (n = 3) or 7 days (n = 3), the baboons were deeply anesthetized with 2% to 3% isoflurane, curarized, and ventilated. Heparin (5000 IU) was administered intravenously. The baboons were placed in a supine position, the thorax was opened through a midline incision, and a cannula was inserted into the ascending aorta through the left ventricle. After incising the right atrium and clamping the descending aorta, heparinized saline was perfused at the baboon's mean arterial pressure until the perfusate from the right atrium was free of formed elements. After decapitation, brain tissues were harvested for both histologic and expression analyzes.

Histologic analysis

After euthanasia, brains were cut into 8 large sagittal slices (1 cm). Slices containing hypometabolic areas then were divided into MRI-related cubes (1 cm³). Tissue samples then were rapidly frozen in isopentane at −50°C and stored at −80°C. Approximately one quarter of each cube sample was cut (20 μm) in a microtome and stained by hematoxylin and eosin for standard histology.

Semiquantitative reverse transcriptase-polymerase chain reaction

Total RNA were harvested from each MRI-related cube by a phenol and chloroform extraction method using the RNaxel extraction kit (Eurobio, Paris, France). Samples (1 μg) then were transcribed into cDNA using poly-dT oligonucleotides. An aliquot of the cDNA was amplified using sense (5′-ccgaagcttgccctggacaccaactattgc) and antisense (5′-ccgtctagagctgcacttgcaggagcg) primers for TGF-β1 (Vivien et al., 1998). For the semiquantitative experiments, an aliquot of the same cDNA libraries was amplified by PCR with specific oligonucleotides for β-actin (sense 5′-gtgggccgctctaggcacaa and antisense 5′-ctctttgatgtcacgcacgatttc). β-Actin was chosen as a housekeeping gene because its transcription is not altered in rodents after experimental cerebral ischemia (Ruocco et al., 1999). Each set of oligonucleotides used gave the PCR product of the expected size (363 bps for TGF-β1 and 540 bps for β-actin). The specificity of the PCR products has been previously confirmed by using restriction digest control and sequencing (Vivien et al., 1998). Amplified products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. Then, PCR products were quantified by optical densitometry and a mean of three independent PCR experiments was calculated for the TGF-β/β-actin ratio for each tissue sample.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting

Fragments of MRI-related cubes were lysed in Tris-NaCl-Triton buffer and centrifuged for 5 minutes (2500 g) to obtain whole cell extracts. Protein concentration was determined in supernatants, with the aid of the BCA protein assay kit (Pierce, Rockford, Illinois). Then, sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed on an equal amount of protein (40 μg), in the absence of reducing agents, before immobilization on a polyvinyl difluoride membrane. Western blotting was applied for 1 hour to the primary antibody (rabbit anti-TGF-β1; kindly provided by Dr. P. ten Dijke; dilution, 1:500), 1 hour to the appropriate secondary biotin-conjugated antibody (dilution, 1:1000), and for 1 hour to Extravidin (1:2000) before revelation using a chemiluminescence kit (NEN, Paris, France).

RESULTS

Twenty-four hours after recovery from MCAO, baboons exhibited variable neurologic deficits (stupor and deviation of the eye and head toward the ipsilateral side) associated with a contralateral hemiparesis. In those animals in which survival was permitted for one week, a near complete restoration of neurologic function was observed.

During all surgical procedures and PET sessions, physiologic parameters were monitored and controlled (Table 1). For each baboon, a control PET session was performed approximately two weeks before the middle cerebral artery occlusion (pre-MCAO CMRO₂, Fig. 1 and 1D) and 24 hours (n = 3) or 7 days (n = 3) after ischemia (post-MCAO CMRO₂, Fig. 1B and 1E). CMRO₂ images presented in Fig. 1 are representative images obtained from animals that displayed an estimated infarct volume representative of that previously obtained in larger series (Touzani et al., 1995). The transposition of the ΔCMRO₂ values (ΔCMRO₂ = post-MCAO CMRO₂ − pre-MCAO CMRO₂) onto the corresponding MRI illustrates the increase in the area of severely hypometabolic tissues (<50% of contralateral mirror-image values) between day 1 and 7 after MCAO (Fig. 1C and 1F, respectively) that has been formerly described in the authors' laboratory (Touzani et al., 1995, 1997). Based on the literature (Touzani et al., 1997), the authors have defined 3 categories of brain tissue as a function of their residual CMRO₂ normalized to their contralateral counterpart. Accordingly, regions with a large (>50%), moderate (20% to 49%), or slight (<20%) reduction in CMRO₂ represented infarcted, ‘penumbral’ border zone, and healthy areas, respectively. The choice of these ‘metabolic thresholds’ was then further validated by histologic analysis based on the microscopic examination of hematoxylin and eosin–stained tissue sections. Tissue samples isolated from regions having a severe reduction of rCMRO₂ exhibited a large eosinophilic area, with a general loss of cellular identity, a homogenous distribution of irreversible ischemic neurons (ghost neurons), and the absence of surviving parenchymal cells. This histologic pattern was consistent with necrotic tissue (Fig. 2C). This infarct core was separated from the areas of normal metabolism and histology (healthy tissue; Fig. 2A) by an intermediate metabolic area (called ‘border zone’) in which reversibly damaged neurons seem predominant (Fig. 2B). Based on the above criteria, the reduced CMRO₂ was then binned and the histologic status of the brain (necrotic, border zone, or healthy) was analyzed as a function of the decrease in CMRO₂ (Fig. 3A and 3B) at both 1 and 7 days after MCAO. These results are in agreement with those presented above in PET images (Fig. 1) showing an increase in the proportion of severely hypometabolic and necrotic tissue between 1 and 7 days after MCAO. These data also provide evidence that 24 hours after the onset of the ischemia, the hypometabolic tissue can be characterized as a penumbral and border zone region with essentially swollen but not dead neurons and only a few necrotic areas.

FIG. 1.

Parametric positron emission tomography (PET) images of cerebral oxygen metabolism (CMRO₂) obtained from a single plane in one anesthetized baboon from each group, that is, before (A and D), 24 hours after (B), or 7 days (E) after right middle cerebral artery occlusion (MCAO) show a progressive expansion of a markedly hypometabolic zone that extends from the core of the MCA territory. The color scale depicts CMRO₂ values (mL 100 g⁻¹ min⁻¹). (C and F) Severely hypometabolic zones (ΔCMRO₂ < 50% of contralateral mirror-image values) transposed onto the corresponding magnetic resonance imaging (MRI) slice (ΔCMRO₂ = post-MCAO CMRO₂ − pre-MCAO CMRO₂).

FIG. 2.

Representative histologic sections showing healthy (A), border zone (B), and necrotic (C) tissues, as revealed by the microscopic examination of hematoxylin and eosin–stained sections. White arrows point out swollen, reversibly damaged neurons, whereas black arrows indicate ghost, irreversibly damaged ischemic neurons. Magnification ×400. Scale bar = 100 μm.

FIG. 3.

Evaluation of the histologic state of the cerebral parenchyma, as a function of the ischemia-induced hypometabolism. For each metabolic threshold (>50%, 20% to 49%, and <20% of reduction of the cerebral oxygen metabolism (CMRO₂)) at 1 day (A) or 7 days postocclusion (B), a systematic histologic analysis allowed the characterization of the histologic status of the magnetic resonance imaging–related cubes. The number of necrotic, border zone, or healthy areas was then normalized to the total number of samples analyzed (n value indicated at the top of each histogram).

TABLE 1.

Biochemical and cardiovascular parameters measured approximately 2 weeks before (pre-MCAO) and 24 hours or 7 days after permanent ischemia (post-MCAO)

	Pre-MCAO	24 hours post-MCAO	Pre-MCAO	7 days post-MCAO
Heart rate (beats/min)	123.1 ± 15.2	118.3 ± 23.6	108.7 ± 23.3	117.9 ± 23.9
MAP (mm Hg)	121.6 ± 28.2	111.2 ± 21.7	117.7 ± 8.1	119.6 ± 28.2
PaCO₂(mm Hg)	40.0 ± 1.2	39.6 ± 0.1	40.2 ± 0.5	39.7 ± 0.9
PaO₂(mm Hg)	114.2 ± 10.3	113.5 ± 12.5	116.4 ± 15.8	119.5 ± 6.5
pH	7.45 ± 0.01	7.43 ± 0.03	7.46 ± 0.03	7.48 ± 0.01
Hb (g/100 mL)	13.7 ± 2.1	13.2 ± 1.0	13.6 ± 1.0	13.6 ± 0.8
Ht (%)	40.2 ± 6.2	38.8 ± 3.0	40.1 ± 3.0	40.0 ± 2.3
[Glu] (g/L)	1.3 ± 0.2	0.9 ± 0.1	1.0 ± 0.1	1.2 ± 0.3
T(°C)	36.5 ± 1.1	37.5 ± 0.5	36.8 ± 0.2	37.1 ± 0.6

Each value is the mean (± SD) of measures performed in three baboons. MCAO, middle cerebral artery occlusion; MAP, mean arterial pressure; Hb, hemoglobin concentration; Ht, hematocrit; [Glu], plasma glucose concentration; T, rectal temperature.

Representative baboons—2 baboons at 24 hours and 1 baboon at 7 days postocclusion—were selected to construct a map of the expression of TGF-β1 mRNA after focal permanent ischemia (Touzani et al., 1997). The two slices that encompassed the majority of hypometabolic and ischemic cubes (as determined by the CMRO₂ images;Fig. 1) were selected for the ensuing analysis. The extraction of total RNA was performed for each. Reverse transcription using poly-dT oligonucleotides (specific of poly-A⁺ mRNA) allowed the constitution of cDNA libraries that were then analyzed by PCR with specific oligonucleotides for β-actin or TGF-β1. An illustration of agarose gel electrophoresis obtained for the expression of TGF-β1 and β-actin mRNA in healthy, border zone and necrotic tissues of the lesioned hemisphere is given in Fig. 4. Contralateral tissue samples were taken from the mirror-image structures. The mean ratio of the optical intensity for the expression of TGF-β1 and β-actin mRNA from three different PCR experiments was calculated for each tissue sample analyzed. Then, the mean of each TGF-β/β-actin ratio for all the tissue samples analyzed were plotted as a function of the decrease in CMRO₂ at both 1 and 7 days after MCAO (Fig. 5A and 5B, respectively). The authors, thus, were able to correlate the expression of TGF-β1 with the degree of ischemia-induced hypometabolism, as well as the probable tissue outcome. Semiquantitative RT-PCR analysis failed to reveal any modification in the expression of TGF-β1 in the nonlesioned contralateral hemisphere (data not shown). In contrast, the current data show in the moderately hypometabolic tissues (reduction of CMRO₂ between 20% to 49%), an increased transcription of TGF-β1 one day post-occlusion (2.8-fold when compared with healthy tissue), that was further enhanced (24.3-fold) 7 days after occlusion. TGF-β1 expression thus was markedly elevated in regions in which the probability of ischemic or necrotic histology was great. This increased transcription of the gene encoding for TGF-β1 was accompanied by an increased level of TGF-β1 protein in moderately and severely hypometabolic tissues isolated in the ischemic side, as compared with contralateral regions (Fig. 6).

FIG. 4.

Representative agarose gel electrophoresis obtained in healthy, border zone, and necrotic tissues submitted to reverse transcription-polymerase chain reaction (RT-PCR) analysis of transforming growth factor-β1 (TGF-β1) and β-actin mRNA expression. Total RNA from healthy, border zone, and necrotic tissues of the lesioned hemisphere, ipsilateral (I) and contralateral (C) to the occluded middle cerebral artery, were isolated and analyzed by RT-PCR for TGF-β1 and β-actin mRNA expression, as described in the Materials and Methods.

FIG. 5.

Semiquantitative analysis of the modulation of the cerebral expression of transforming growth factor-β1 (TGF-β1) mRNA as a function of the severity of hypometabolism induced by focal permanent ischemia in the baboon. Total RNA from brain tissue samples (magnetic resonance imaging-related cubes) were isolated at the time indicated after middle cerebral artery occlusion and analyzed by reverse transcription polymerase chain reaction (RT-PCR) for TGF-β1 and β-actin mRNA expression. Two individual animals were used at 1 day (A) and 1 animal at 7 days (B) postocclusion. Histogram values are presented as the mean ratio between TGF-β1 and β-actin, calculated from three independent PCR experiments performed on n samples (n value indicated at the top of each bar graph) analyzed in each metabolic category. CMRO₂, cerebral oxygen metabolism.

FIG. 6.

Increased expression of transforming growth factor-β1 (TGF-β1) in hypometabolic tissues induced by focal permanent ischemia in the baboon, as evidenced by Western blotting performed from contralateral (C), moderately hypometabolic (MH), or severely hypometabolic (SH) tissues, revealed with an antibody raised against TGF-β1. MW, molecular weight.

Taken together, these data provide for the first time a partial brain mapping of the expression of the previously characterized injury-related neuroprotective peptide, TGF-β1, in relation to the ischemia-induced disturbances of oxygen metabolism.

DISCUSSION

The noninvasive technology of PET has been developed to accurately evaluate and map regional hemodynamic and metabolic parameters. Positron emission tomography imaging thus represents a powerful tool to improve the pathophysiologic diagnosis of cerebrovascular disorders, such as stroke (Ueda et al., 1999). It is generally admitted that the metabolism of oxygen reflects an oxygen supply adapted to the metabolic needs of the tissue (Baron et al., 1984). The PET oxygen-15 steady-state method, which, in a single PET session, measures serially and at the regional level, cerebral blood flow, cerebral blood volume, oxygen extraction faction, and CMRO₂, thus allows to delineate cerebral regions (ischemic core, penumbra, or healthy areas) as a function of the degree of hypoperfusion and hypometabolism. In the current study, the authors have thus attempted to correlate the extent of metabolic changes with the expression of the neuroprotective cytokine, TGF-β1. As such, the authors combined PET imaging and biomolecular and cellular technologies in the baboon brain 24 hours and 7 days after the onset of focal permanent ischemia.

The first finding of the current study suggests that it is possible to correlate the gene expression of the injury-related cytokine, TGF-β1, with the metabolic and histologic tissue outcome after an ischemic insult in the brain. Moreover, the current study supports the authors' previous reports derived from rodent models, which show that the endogenous production of TGF-β1 is a pivotal indicator of the extent of ischemic brain damage (Ruocco et al., 1999). To the authors' knowledge, no previous study in the nonhuman primate has evaluated, in a reliable model of focal ischemia, the metabolic and histologic parameters in comparison with the expression of a gene thought to play a role in infarct progression.

Various studies have related an increased expression of TGF-β1 in brain tissues after different types of acute brain injury, including cerebral ischemia, for which most of the available data have been obtained from rodent models (Wang et al., 1995; Knuckey et al., 1996; Lehrmann et al., 1998). In the current study, the authors confirmed that TGF-β1 is overexpressed after cerebral ischemia in the baboon. Previous studies conducted in rodent models of focal ischemia have suggested that the synthesis of TGF-β may originate from resident (astrocytes, microglia, neurons, and endothelial cells) and infiltrated (macrophages) cells (Lehrmann et al., 1995; Ata et al., 1999). A similar cellular pattern has been reported in humans after stroke (Krupinski et al., 1996). In addition, the current results evidenced that this induction of TGF-β1 is essentially located in those zones that display a moderate hypometabolism (as shown by a decrease in the CMRO₂ ranging from 20% to 49%) and an histologic pattern mainly exhibiting neurons that displayed early ischemic damage with nevertheless some irreversibly damaged ischemic cells. This current observation is agrees with a previous report published by Krupinski and collaborators (1996), which demonstrated an increased immunoreactivity for TGF-β1 in the infarcted and penumbral brain areas after ischemic stroke in humans. However, in that study, the authors did not correlate this production of protein with either metabolic or histologic analyses.

Transforming growth factor-β1, endogenously produced by the cerebral parenchyma after ischemic injury, has been postulated to be of critical importance, but its role after brain damage remains to be clearly established. In vivo, the intracerebroventricular application of TGF-β decreases infarction volume after MCAO in the mouse (Prehn et al., 1993). The authors have recently assessed the relevance of the endogenous synthesis of TGF-β1 by the blockade of its biologic activity achieved by the injection of a soluble TGF-β type II receptor (Ruocco et al., 1999). Through this strategy, the authors found that TGF-β1 limits the extent of ischemic or excitotoxic lesions in the rat. Overall, the current data demonstrate that TGF-β1 exhibits an endogenous neuroprotective activity against ischemic brain insults. Nevertheless, the molecular and cellular mechanisms of TGF-β1 involvement during neurologic disorders such as stroke have not yet been fully resolved. Among the various possibilities, it has been suggested that TGF-β may exert neurotrophic effects (Blottner et al., 1996; Iwasaki et al., 1997; Krieglstein et al., 1998), display neuroprotective activity against excitotoxic paradigms (Prehn et al., 1993; Buisson et al., 1998; Ruocco et al., 1999; Ho et al., 2000), modulate astrocytic reactivity (Lindholm et al., 1992; Rich et al., 1999), regulate extracellular matrix metabolism (McCaffrey et al., 1995; Basile et al., 1998), and control thrombolysis (Fujii and Sobel, 1992; Thomas and Thibodaux, 1992).

Given the importance of the excitotoxic cascade in the development of cerebral ischemia, antiglutamatergic strategies were proposed as the first rational treatment of stroke; these therapeutic approaches have been unsuccessful largely because of secondary effects (De Keyser et al., 1999). Currently, the sole approved clinical therapy for stroke patients is in the administration of the thrombolytic agent, t-PA (tissue-type plasminogen activator). However, there is an ever-present interest in the development of alternative strategies that are primarily directed toward the modulation of the endogenous pathways involved in ischemic processes. One such strategy would be aimed to potentiate endogenous neuroprotective cytokines, such as TGF-β1. The approach used in the current investigation thus may represent a powerful tool in understanding the mechanisms of action of TGF-β1 during cerebral ischemia and to validate the authors' hypothesis that TGF-β1 may be a target for the development of therapeutic strategies against human stroke.

Footnotes

Acknowledgments:

The authors thank all of the members of the Cyclotron Unit at Cyceron for their technical expertise and Dr. P. Karamian for his kind and helpful comments.

References

Ata

Lennmyr

Funa

Olsson

Terent

(1999) Expression of transforming growth factor-beta1, 2, 3 isoforms and type I and II receptors in acute focal cerebral ischemia: An immunohistochemical study in rat after transient and permanent occlusion of middle cerebral artery. Acta Neuropathol (Berl) 97:447–455

Attisano

Wrana

(2000) Smads as transcriptional co-modulators. Curr Opin Cell Biol 12:235–243

Baron

Rougemont

Soussaline

Bustany

Crouzel

Bousser

Comar

(1984) Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: A positron tomography study. J Cereb Blood Flow Metab 4:140–149

Basile

Martin

Hammerman

(1998) Extracellular matrix-related genes in kidney after ischemic injury: Potential role for TGF-beta in repair. Am J Physiol 275:F894–F903

Blottner

Wolf

Lachmund

Flanders

Unsicker

(1996) TGF-beta rescues target-deprived preganglionic sympathetic neurons in the spinal cord. Eur J Neurosci 8:202–210

Bonewald

(1999) Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr 9:33–44

Buisson

Nicole

Docagne

Sartelet

MacKenzie

Vivien

(1998) Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta1. FASEB J 12:1683–1691

Choi

(1996) Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 6:667–672

DeGraba

(1998) The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy. Neurology 51: S62–S68

10.

De Keyser

Sulter

Luiten

(1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci 22:535–540

11.

Docagne

Nicole

Marti

MacKenzie

Buisson

Vivien

(1999) Transforming growth factor beta-1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 13:1315–1324

12.

Feuerstein

Wang

Barone

(1998) The role of cytokines in the neuropathology of stroke and neurotrauma. Neuroimmunomodulation 5:143–159

13.

Frackowiak

Lenzi

Jones

Heather

(1980) Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: Theory, procedure, and normal values. J Comput Assist Tomogr 4:727–736

14.

Fujii

Sobel

(1992) Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 85:1888–1893

15.

Henrich-Noack

Prehn

Krieglstein

(1996) TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 27:1609–1614

16.

Bristol

Coccia

Milbrandt

Johnson

Jin

Bar-Peled

Griffin

Rothstein

(2000) TGFbeta trophic factors differentially modulate motor axon outgrowth and protection from excitotoxicity. Exp Neurol 161:664–675

17.

Iwasaki

Shiojima

Tagaya

Kobayashi

Kinoshita

(1997) Effect of transforming growth factor beta 1 on spinal motor neurons after axotomy. J Neurol Sci 147:9–12

18.

Knuckey

Finch

Palm

Primiano

Johanson

Flanders

Thompson

(1996) Differential neuronal and astrocytic expression of transforming growth factor beta isoforms in rat hippocampus following transient forebrain ischemia. Brain Res Mol Brain Res 40:1–14

19.

Krieglstein

Farkas

Unsicker

(1998) TGF-beta regulates the survival of ciliary ganglionic neurons synergistically with ciliary neurotrophic factor and neurotrophins. J Neurobiol 37:563–572

20.

Krupinski

Kumar

Kaluza

(1996) Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke 27:852–857

21.

Lehrmann

Kiefer

Finsen

Diemer

Zimmer

Hartung

(1995) Cytokines in cerebral ischemia: Expression of transforming growth factor beta-1 (TGF-beta 1) mRNA in the postischemic adult rat hippocampus. Exp Neurol 131:114–123

22.

Lehrmann

Kiefer

Christensen

Toyka

Zimmer

Diemer

Hartung

Finsen

(1998) Microglia and macrophages are major sources of locally produced transforming growth factor beta-1 after transient middle cerebral artery occlusion in rats. Glia 24:437–448

23.

Lindholm

Castren

Kiefer

Zafra

Thoenen

(1992) Transforming growth factor-beta 1 in the rat brain: Increase after injury and inhibition of astrocyte proliferation. J Cell Biol 117:395–400

24.

Massague

(1990) The transforming growth factor-beta family. Ann Rev Cell Biol 6:597–641

25.

Massague

(1996) TGFbeta signaling: Receptors, transducers, and Mad proteins. Cell 85:947–950

26.

Massague

Wotton

(2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745–1754

27.

McCaffrey

Consigli

Falcone

Sanborn

Spokojny

Bush

Jr (1995) Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest 96:2667–2675

28.

Pratt

McPherson

(1997) TGF-beta in the central nervous system: Potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev 8:267–292

29.

Prehn

Backhauss

Krieglstein

(1993) Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Metab 13:521–525

30.

Prehn

Bindokas

Marcuccilli

Krajewski

Reed

Miller

(1994) Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. Proc Natl Acad Sci U S A 91:12599–12603

31.

Prehn

Miller

(1996) Opposite effects of TGF-beta 1 on rapidly-and slowly-triggered excitotoxic injury. Neuropharmacology 35:249–256

32.

Rich

Zhang

Datto

Bigner

Wang

(1999) Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 274:35053–35058

33.

Ruocco

Nicole

Docagne

Ali

Chazalviel

Komesli

Yablonsky

Roussel

MacKenzie

Vivien

Buisson

(1999) A transforming growth factor beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J Cereb Blood Flow Metab 19:1345–1353

34.

Sette

Baron

Mazoyer

Levasseur

Pappata

Crouzel

(1989) Local brain haemodynamics and oxygen metabolism in cerebrovascular disease. Positron emission tomography. Brain 112:931–951

35.

Ten Dijke

Miyazono

Heldin

(2000) Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 25:64–70

36.

Thomas

Thibodaux

(1992) Transforming growth factor-beta 1 inhibits postischemic increases in splanchnic vascular resistance. Biotechnol Ther 3:91–100

37.

Touzani

Young

Derlon

Beaudouin

Marchal

Rioux

Mezenge

Baron

MacKenzie

(1995) Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion. A positron emission tomographic investigation in anesthetized baboons. Stroke 26:2112–2119

38.

Touzani

Young

Derlon

Baron

MacKenzie

(1997) Progressive impairment of brain oxidative metabolism reversed by reperfusion following middle cerebral artery occlusion in anaesthetized baboons. Brain Res 767:17–25

39.

Ueda

Yuh

Maley

Otake

Quets

Taoka

Hahn

White

(1999) Current and future imaging of acute cerebral ischemia: Assessment of tissue viability by perfusion imaging. J Comput Assist Tomogr 23(suppl 1):S3–S7

40.

Vivien

Bernaudin

Buisson

Divoux

MacKenzie

Nouvelot

(1998) Evidence of type I and type II transforming growth factor-beta receptors in central nervous tissues: Changes induced by focal cerebral ischemia. J Neurochem 70:2296–2304

41.

Wang

Yue

White

Barone

Feuerstein

(1995) Transforming growth factor beta-1 exhibits delayed gene expression following focal cerebral ischemia. Brain Res Bull 36:607–609

42.

Young

Sette

Touzani

Rioux

Derlon

MacKenzie

Baron

(1996) Relationships between high oxygen extraction fraction in the acute stage and final infarction in reversible middle cerebral artery occlusion: An investigation in anesthetized baboons with positron emission tomography. J Cereb Blood Flow Metab 16:1176–1188

43.

Zimmerman

Padgett

(2000) Transforming growth factor beta signaling mediators and modulators. Gene 249:17–30